Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin adjunct to lifestyle intervention for cardiometabolic health in young people with mood or psychotic syndromes
ACTRN12619001559101Phase 4Not yet recruiting
- Sponsor
- University of Sydney
- Start
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in insulin resistance (IR), Overweight, obesity and 6 more comparing Metformin + HLBMI with Placebo + HLBMI (2 arms). Primary endpoint: HOMA2-IR score. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
insulin resistance (IR)Overweightobesityaffective disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on ACTRN12619001559101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001559101.